文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症心脑血管急症

不同肠内营养制剂在重型颅脑损伤患者中应用的临床观察

[Clinical observation on application of different enteral nutrition preparations in patients with severe traumatic brain injury].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2019-01-01
一句话结论回顾性分析显示,重型颅脑损伤患者使用短肽肠内营养(百普力)胃肠道耐受更好,但血糖波动更大;含ω-3脂肪酸的整蛋白肠内营养(瑞能)血糖波动较小且可缩短机械通气时间和ICU住院时间。

该回顾性分析纳入2016年1月至2018年5月贵州医科大学附属医院ICU收治的重型颅脑损伤(GCS<8)并接受肠内营养的患者95例,其中百普力组30例、瑞能组35例、瑞素组30例,肠内营养在转入ICU后48小时内开始,以83.68-104.60 kJ×kg-1×d-1为营养支持目标。结果显示三组血红蛋白、淋巴细胞计数、血清白蛋白、降钙素原无显著差异;百普力组前白蛋白较高但平均血糖和血糖变异系数更高,胃肠道耐受指标更好(更早达到目标喂养时间、胃潴留和消化道出血发生率更低);瑞能和百普力组机械通气时间及ICU住院时间长于瑞能组;院内感染发生率三组无显著差异。结论认为短肽肠内营养(百普力)胃肠道耐受更好但可致血糖波动,含ω-3脂肪酸的整蛋白肠内营养(瑞能、瑞素)对血糖影响较小,瑞能可缩短机械通气时间和ICU住院时间,更适合此类患者。

要点

  • 百普力组第7天前白蛋白高于瑞能组和瑞素组(mg/L:275.55±46.18 vs. 238.25±49.59、240.70±55.59,均P<0.05)。
  • 百普力组平均血糖和血糖变异系数高于瑞能组和瑞素组[平均血糖(mmol/L):10.02±2.39 vs. 8.53±1.53、8.98±1.75;血糖变异系数:(23.59±3.93)% vs.(14.79±3.65)%、(17.88±2.90)%,均P<0.05]。
  • 百普力组达到目标喂养时间早于瑞能组和瑞素组(天:4.40±1.20 vs. 5.50±1.07、5.45±1.02,均P<0.05),胃潴留和消化道出血发生率均降低[6.67%(2/30) vs. 31.43%(11/35)、33.33%(10/30);3.33%(1/30) vs. 14.29%(5/35)、16.67%(5/30),均P<0.05]。
  • 瑞素组和百普力组机械通气时间和ICU住院时间长于瑞能组[机械通气时间(天):6.94±1.64、6.79±1.14 vs. 5.93±1.12;ICU住院时间(天):9.40±2.18、10.40±2.35 vs. 7.45±1.83,均P<0.05]。
  • 三组呼吸机相关性肺炎、导管相关血流感染、尿路感染、颅内感染发生率无显著差异(均P>0.05)。

适用人群与场景

  • 2016年1月至2018年5月贵州医科大学附属医院ICU收治的重型颅脑损伤患者,GCS<8,均接受肠内营养,共95例(百普力组30例、瑞能组35例、瑞素组30例),为回顾性分析。

诊断标准与关键阈值

  • 重型颅脑损伤诊断标准:GCS<8。
  • 营养支持目标:能量摄入83.68-104.60 kJ×kg-1×d-1。

处置流程与药物剂量

  • 肠内营养在患者转入ICU后48小时内开始。
  • 百普力组给予百普力肠内营养,瑞能组给予瑞能肠内营养,瑞素组给予瑞素肠内营养。
  • 肠内营养支持7天后观察血红蛋白、淋巴细胞计数、血清白蛋白、前白蛋白、降钙素原、平均血糖和血糖变异系数,记录肠内营养达标时间及胃肠道耐受情况,比较机械通气时间、ICU住院时间和院内感染发生率。

红旗征与不能漏的情况

  • 百普力组胃潴留发生率6.67%(2/30) vs. 瑞能组31.43%(11/35)、瑞素组33.33%(10/30),均P<0.05。
  • 百普力组消化道出血发生率3.33%(1/30) vs. 瑞能组14.29%(5/35)、瑞素组16.67%(5/30),均P<0.05。
  • 百普力组平均血糖(mmol/L)10.02±2.39 vs. 瑞能组8.53±1.53、瑞素组8.98±1.75,血糖变异系数(23.59±3.93)% vs.(14.79±3.65)%、(17.88±2.90)%,均P<0.05。

研究设计与关键结果

  • 回顾性分析共纳入95例重型颅脑损伤(GCS<8)患者,百普力组30例、瑞能组35例、瑞素组30例。
  • 治疗7天后三组血红蛋白、淋巴细胞计数、血清白蛋白、降钙素原无明显变化,组间差异无统计学意义。
  • 百普力组前白蛋白显著高于瑞能组和瑞素组(mg/L:275.55±46.18 vs. 238.25±49.59、240.70±55.59,均P<0.05)。
  • 百普力组平均血糖和血糖变异系数显著高于瑞能组和瑞素组[平均血糖(mmol/L):10.02±2.39 vs. 8.53±1.53、8.98±1.75;血糖变异系数:(23.59±3.93)% vs.(14.79±3.65)%、(17.88±2.90)%,均P<0.05]。
  • 百普力组胃肠道耐受指标优于瑞能组和瑞素组:达到目标喂养时间提前(天:4.40±1.20 vs. 5.50±1.07、5.45±1.02,均P<0.05),胃潴留和消化道出血发生率均降低[胃潴留:6.67%(2/30) vs. 31.43%(11/35)、33.33%(10/30);消化道出血:3.33%(1/30) vs. 14.29%(5/35)、16.67%(5/30),均P<0.05]。
  • 瑞素组和百普力组机械通气时间和ICU住院时间长于瑞能组[机械通气时间(天):6.94±1.64、6.79±1.14 vs. 5.93±1.12;ICU住院时间(天):9.40±2.18、10.40±2.35 vs. 7.45±1.83,均P<0.05]。
  • 三组院内感染发生率无显著差异[呼吸机相关性肺炎:瑞能组11.43%、瑞素组10.00%、百普力组10.00%;导管相关血流感染:0、0、3.33%;尿路感染:5.71%、6.67%、6.67%;颅内感染:2.86%、6.67%、3.33%,均P>0.05]。

证据类型、等级与局限

  • 证据类型:回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于重型颅脑损伤患者,短肽肠内营养制剂(百普力)胃肠道耐受性更好,但可引起血糖波动;含ω-3脂肪酸的整蛋白肠内营养(瑞能、瑞素)对血糖波动影响相对较小,瑞能可缩短机械通气时间和ICU住院时间,因此更适合此类患者应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the effects of enteral nutrition (EN) emulsion with different components on nutritional index, blood glucose, inflammatory reaction, gastrointestinal tolerance and prognosis in patients with severe traumatic brain injury (sTBI).

METHODS: Patients with sTBI [Glasgow coma scale (GCS) < 8] admitted to intensive care unit (ICU) of Affiliated Hospital of Guizhou Medical University from January 2016 to May 2018 were retrospectively analyzed. These patients had received EN, 30 cases of them were fed with Baipuli, 35 cases were fed with Ruineng, and 30 cases were fed with Ruisu. The EN support began within 48 hours after the patients were transferred to ICU, and the energy intake of 83.68-104.60 kJ×kg-1×d-1 was the nutritional support target. The hemoglobin (Hb), lymphocyte count (LYM), serum albumin (Alb), pre-albumin (PA), procalcitonin (PCT), average blood glucose (GLUave) and blood glucose variation coefficient (GLUcv) were observed 7 days after EN support, EN compliance time, gastrointestinal tolerance situations were recorded, and the duration of mechanical ventilation (MV), the length of ICU stay and incidence of nosocomial infection were compared among the three groups.

RESULTS: There were no obvious changes in Hb, LYM, Alb, PCT among three groups after treatment on the 7th day, and there was no significant difference among the three groups. The PA of Baipuli group was significantly higher than that in Ruineng and Ruisu groups at 7 days after treatment (mg/L: 275.55±46.18 vs. 238.25±49.59, 240.70±55.59, both P < 0.05), but the GLUave and GLUcv were much higher than those in Ruineng and Ruisu groups [GLUave (mmol/L): 10.02±2.39 vs. 8.53±1.53, 8.98±1.75; GLUcv: (23.59±3.93)% vs. (14.79±3.65)%, (17.88±2.90)%, all P < 0.05]. The indexes of gastrointestinal tolerance in Baipuli group were better than those of Ruineng and Ruisu groups: the target feeding time was reached ahead (days: 4.40±1.20 vs. 5.50±1.07, 5.45±1.02, both P < 0.05), the incidence of gastric retention and digestive tract hemorrhage were both decreased [6.67% (2/30) vs. 31.43% (11/35), 33.33% (10/30); 3.33% (1/30) vs. 14.29% (5/35), 16.67% (5/30), all P < 0.05]. The duration of MV and the length of ICU stay in Ruisu and Baipuli groups were longer than those of Ruineng group [duration of MV (days): 6.94±1.64, 6.79±1.14 vs. 5.93±1.12; the length of ICU stay (days): 9.40±2.18, 10.40±2.35 vs. 7.45±1.83, all P < 0.05]. There was no significant difference in the incidences of nosocomial infection among Ruineng, Ruisu, and Baipuli groups [the incidence of ventilator-associated pneumonia (VAP): 11.43%, 10.00%, 10.00%; catheter related bloodstream infection: 0, 0, 3.33%; urinary tract infection: 5.71%, 6.67%, 6.67%; intracranial infection: 2.86%, 6.67%, 3.33%, all P > 0.05].

CONCLUSIONS: For patients with sTBI, short peptide EN preparations (Baipuli) is much better in gastrointestinal tolerance but it can cause fluctuations of blood glucose; the whole protein EN containing ω-3 fatty acid (Ruineng, Ruisu) has relatively less fluctuation on blood glucose, the duration of MV and the length of ICU stay can be shortened by Ruineng, therefore it is more suitable to be applied for such patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Wang Y, Wang D, Fu J, et al. [Clinical observation on application of different enteral nutrition preparations in patients with severe traumatic brain injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 30827311. doi:10.3760/cma.j.issn.2095-4352.2019.02.017

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。